Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Henan Lingrui Pharmaceutical Co's average EPS without NRIGrowth Rate was 5.40% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 20.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 20.00% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 18.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Henan Lingrui Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 61.30% per year. The lowest was -18.40% per year. And the median was 15.80% per year.
Henan Lingrui Pharmaceutical Co (SHSE:600285) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Henan Lingrui Pharmaceutical Co EPS (Diluted) Related Terms
Henan Lingrui Pharmaceutical Co EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co EPS (Diluted) Chart
SHSE:600285 vs ZTS, UTHR: EPS (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Lingrui Pharmaceutical Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Henan Lingrui Pharmaceutical Co's PE Ratio falls into.
Henan Lingrui Pharmaceutical Co EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Lingrui Pharmaceutical Co (SHSE:600285) has a EPS (Diluted) of ¥1.39 as of Mar. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Henan Lingrui Pharmaceutical Co and its competitors.
Is Henan Lingrui Pharmaceutical Co's EPS (Diluted) too high?
Henan Lingrui Pharmaceutical Co's current EPS (Diluted) is ¥1.39. Overall, Henan Lingrui Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Henan Lingrui Pharmaceutical Co's EPS (Diluted) compare to ZTS and UTHR?
Henan Lingrui Pharmaceutical Co's EPS (Diluted) of ¥1.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Henan Lingrui Pharmaceutical Co and its competitors. Henan Lingrui Pharmaceutical Co's current EPS (Diluted) is ¥1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Lingrui Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co (SHSE:600285) is currently considered Fairly Valued. The stock's GF Value™ is ¥24.42, compared to a current price of ¥22.40 — trading 8.3% below its estimated fair value. The current EPS (Diluted) is ¥1.39. Henan Lingrui Pharmaceutical Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Henan Lingrui Pharmaceutical Co (SHSE:600285), the current EPS (Diluted) is ¥1.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Lingrui Pharmaceutical Co (SHSE:600285) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Lingrui Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥22.40 is trading 8.3% below its estimated GF Value™ of ¥24.42.
GuruFocus considers Henan Lingrui Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600285:
EPS (Diluted): ¥1.39
GF Value™: ¥24.42 vs. price of ¥22.40 (8.3% below fair value)
No single metric tells the full story. See the SHSE:600285 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Lingrui Pharmaceutical Co Business Description
Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.
92GF Score
Get the complete analysis for SHSE:600285
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600285 has been successfully added to your 
